Morphology of Endogenous Flare-up Reactions in Contact Allergy to Gold

ÅKE LARSSON¹, HALVOR MÖLLER², BERT BJÖRKNER² and MAGNUS BRUZE²

Departments of ¹Oral Pathology, Centre for Oral Health Sciences, and ²Dermatology, Malmö University Hospital, Lund University, Malmö, Sweden

In a double-blind study, 20 patients with contact allergy to gold were given an intramuscular injection of gold sodium thiosulfate or placebo, inducing a clinical and histological flare-up of healed patch test sites in the gold-injected but not in the placebo group. The test area of the placebo group showed some perivascular lymphocytic foci (UCHL-1+) and vascular endothelial ELAM-1 staining. The gold group, with flare-up, showed larger and more extensive lymphocytic foci with ELAM-1 + endothelium as well as lymphocytic epidermotropism. CD1a + LC cells were downregulated, tryptase + mast cells accumulated and CD68 + monocytes/macrophages markedly increased. Probably, a significant part of the tissue priming as a result of patch testing comprises memory T-cells and endothelial ELAM-1 upregulation, but blood-borne CD68 + monocytes may also be instrumental in the flare-up. Key words: skin; immunocytochemistry.

(accepted June 6, 1997)

Acta Derm Venereol (Stockh) 1997; 77: 474-479.
Åke Larsson, Department of Oral Pathology, Centre for Oral Health Sciences, S-214 21 Malmö, Sweden.

Eczematous flare-up reactions frequently occur during the course of allergic contact dermatitis. This implies a reactivation of a previous contact dermatitis, be that accidental at an earlier site of e.g. a nickel-containing buckle, or intentional at a former patch test site. Flare-up reactions are easily provoked by systemic exposure to the allergen. Pompomphylitis is a common clinical expression of such a flare-up, but exacerbating eczematous patches may occur anywhere on the body (1).

Contact allergy to gold sodium thiosulfate (GSTS) has recently been recorded in high frequency among patients routinely patch-tested for eczematous disease (2–4). Patients with contact allergy to GSTS also react to gold sodium thiosulfate (GSTM), epicutaneously as well as intradermally (5). We have recently shown (6) that patients with contact allergy to gold regularly react with different cutaneous and general symptoms and signs when exposed parenterally to GSTM.

Although clinically important, the pathogenesis of the cutaneous flare-up in contact dermatitis has not been sufficiently clarified. In order to obtain a better understanding of the skin membrane function in contact allergy, the flaring skin as well as its quiescent base have been studied in the present work by morphological methods, using contact allergy to gold as a model.

MATERIAL AND METHODS

Twenty patients patch-tested with a standard series and found positive to GSTS (0.5% pet) were invited to a double-blind provocation study. Informed consent was obtained, as well as permission from the Ethics committee of the Lund University Medical Faculty.

The patients were patch-tested with serial aqueous dilutions of GSTS (Chemotechnique Diagnostics) and GSTM (Rhône-Poulenc Rorer), stepwise by a factor of √10, starting with 5% and 36%, respectively. In preliminary (unpublished) observations these test concentrations had been shown to be non-irritant. The patients were also tested with auranofin (Ridaura® SmithKline Beecham) 47%, the highest dispersible concentration. If the patient at the preliminary patch test had also shown a positive reaction to another standard allergen, this was now repeated. Thus, 5 subjects were in addition tested with nickel sulfate, and one each with cobalt chloride, neomycin sulfate, p-phenylendiamine base, and the preservatives Kathon CG, thimerosal, and Eucyl K 400.

The patch tests were applied for 48 h with Finn chambers® on Scanpor®. Since patch test reactions to gold salts usually are long-lasting and often develop late (7), they were read on day 7 only.

Five weeks later, i.e. 6 weeks after the test application, the patients were examined and residual test reactions recorded. They were then given an intramuscular injection of GSTM (Myocristin® Rhône-Poulenc Rorer) 0.5 ml of a 20 mg/ml solution or placebo. Two days after the GSTM/placebo injection the patients were examined for cutaneous or general reactions. Two-millimetre punch biopsies were taken for routine histopathology and immunohistochromistry, usually two of each type, from test reactions and/or clinical flare-ups (rashes), and transferred to formalin or fresh-frozen.

Immunohistochromistry

Biopsies were fresh-frozen in isopentane at −80°C. Six-μm frozen sections were air-dried, fixed for 10 min in acetone and washed in PBS. Endogenous peroxidase was blocked by treatment with 3% H₂O₂ in PBS for 30 min, followed by 1% normal rabbit serum in PBS for 30 min to block non-specific background staining. Primary monoclonal antibodies (anti CD45RO + UCHL-1, DAKO; anti HLADR: clone CR3/43, DAKO; anti human mast cell tryptase: clone AA1, DAKO; anti intercellular adhesion molecule-1, ICAM-1/CD54, Immunotech; anti-E-selectin-endothelial leukocyte adhesion molecule-1/ELAM-1, CD62E, Immunotech; FXIIIa, Behring, S-100, DAKO; CD1a, Immunotech; CD68, DAKO) were applied at optimal dilutions for 60 min at room temperature or overnight at 4°C. Following a PBS rinse, the sections were incubated with HRP-conjugated rabbit anti-mouse IgG (Dako) in PBS. ELAM-1 detection was also performed with the ABC technique. Anti-tryptase incubations were preceded by trypsin treatment. Bound peroxidase was revealed with 0.01% H₂O₂ (30 min), and the sections were counterstained with Mayer's haematoxylin and mounted.

RESULTS

At 48 h after the parenteral provocation, the patch tests were reactivated in 9/10 patients after receiving the active agent GSTM but in none after placebo (Table 1). These flare-ups were observed by the patients after only 4–6 h after the injection, as a strong itch on the test area of the back. At 48 h, the test sites were activated with a vigorous dermatitis of a dermal, often oedematous character (Fig. 1), in a few cases also epidermal/eczematous. In the non-reacting tests

© 1997 Scandinavian University Press. ISSN 0001-5555
Table 1. Clinical reactions and 40 biopsy sites in 20 patients with contact allergy to gold given one intramuscular injection (IM) with gold (G) or placebo (P)

<table>
<thead>
<tr>
<th>Pat no.</th>
<th>IM</th>
<th>Clinical flare-up as fever and/or rash, eczema</th>
<th>Reactivation of GSTS test</th>
<th>Biopsy from rash or eczema</th>
<th>Skin test GSTM</th>
<th>GSTS</th>
<th>Aura</th>
<th>ST</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>P</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GSTS = gold sodium thiosulfate; GSTM = gold sodium thiomalate; Aura = auranofin; ST = standard allergen; ID = old intradermal gold test.

Fig. 1. Positive patch tests to gold sodium thiosulfate and gold sodium thiomalate in serial dilutions, abated since 6 weeks but reactivated by an intramuscular injection of 10 mg gold sodium thiomalate. Dermal as well as epidermal features may be observed 48 h later.

There was, even 6 weeks after application, some slight postinflammatory change facilitating identification.

A toxicoderma-like rash occurred in 7/10 patients given the active agent vs 1/10 after placebo. A high but transient fever occurred in 8/10 after GSTM but in none after placebo. The clinical reactions have been presented in detail separately (6).

Forty duplicate biopsies were taken blindly from test areas and rashes according to Table I. Among 4 patients tested intradermally 9–24 months previously with GSTS, 2 had received a GSTM injection and both showed a flare-up, in contrast to no flare-up in the other 2 given placebo. These intradermal flare-ups showed dense lymphocytic infiltrates perivascularly in the reticular dermis but insignificant reaction in the papillary dermis. Routine-stained sections of biopsies from the 4 patients with patch test reactions to standard allergens, as well as the 2 with a toxicoderma-like rash, showed only a few perivascular foci of lymphocytic cells in the upper reticular/papillary dermis, regardless if the systemic provocation had been carried out with gold or placebo. In the 3 cases with test reactions to auranofin, the perivascular lymphocytic infiltration was more pronounced, at least in the 2 patients who received the active agent. These 9 biopsies were not further analysed immunocytochemically.

Biopsies were taken from 9 of the 10 patients receiving a GSTM injection, and in 8 of these 9 a clinical flare-up of the tests had been observed. In total, the GSTM test site was biopsied in 17 patients. In 6/17 there was a weak inflammation, all after placebo, and among the other 11 patients there was a single gold-challenged case, in which the clinical symptoms required corticosteroid treatment. In this case, the subsequent biopsy showed a PMN- and eosinophil-rich infiltration. In the remaining 2 placebos and 8 gold-challenged cases, biopsies showed varying degrees of focal mononuclear cell infiltrates, perivascularly at the superficial plexus. No difference in the histopathological picture was observed between the flaring GSTM and GSTS reactions.

The placebo group (Fig. 2a–f) showed a small number of focal moderately sized dermal infiltrates (Fig. 2a) ofUCHL1+ (Fig. 2b) and HLADR+ lymphocytic cells, and the vascular endothelium at these foci stained with ELAM-1 (Fig. 2c). A small number of tryptase+ cells were evenly distributed in the papillary and reticular dermis but also at the lymphocytic infiltrates (Fig. 2d). In the epidermis, LC-like dendritic cells stained positively with CD1a (Fig. 2e), S-100 and HLADR but negatively with FXIII and CD68. In the dermis, only an occasional CD1a-stained cell could be demonstrated, whereas S-100-, CD68- and HLADR-stained cells were readily ob-

Acta Derm Venereol (Stockh) 77
served, the two latter mainly in the papillary dermis (Fig. 2f).

Many of the stained dermal cells were associated with the lymphocytic infiltrates.

The GSTM group showed endothelial ELAM-1 staining similar to the placebo (not illustrated) but differed from the placebo in the following way (Fig. 2g-m). Lymphocytic, UCHL1+, and HLADR+ peri-vascular infiltrates were larger, also with a more extensive involvement of reticulate dermis. Papillary dermis showed oedema, occasionally with a few PMN, and lymphocytic epidermotropism was accompanied by ICAM-1 staining of basal epidermal cells and occasional apoptotic basal cells (Fig. 2h). Epidermal and dermal S-100+ + and HLADR+ + cells were present but staining seemed slightly irregular. A significant number of dendritic-shaped HLADR+ cells appeared in the papillary dermis, and S-100 + cells tended to accumulate at the papillary dermal lymphocytic infiltrates. S-100 stained nerves were invariably demonstrated within these infiltrates, also seen in the placebo group. Also, FXIII + cells tended to accumulate at the lymphocytic infiltrates and in the oedematous papillary dermis (Fig. 2i). In the dermis, most of the tryptase + mast cells were associated with the lymphocytic infiltrates (Fig. 2k), where some of them showed evidence of degranulation. In the epidermis, CD1a staining was weak and stained cells were unevenly distributed (Fig. 2i), with only an occasional stained cell in the dermis. The number of CD68-stained cells and dendritic-shaped dermal cells was increased, the majority associated with the lymphocytic loci (Fig. 2m).

DISCUSSION

Au(III) may via its reactive intermediate metabolite Au(III) induce alterations in unidentified self-proteins, resulting in an activation, in sensitive subjects, of T-cells to cryptic self-peptides (8, 9). Such "Au(III)-specific" T-cells are likely to be involved in contact allergy to Au(1) (cf 10) as well as in adverse reactions to Au(1) drugs (8, 11). Reactivation of a memory pool of "metal-specific" T-cells should therefore be expected to occur in a contact allergic (patch test-positive) individual following a systemic administration of Au(1). Such activated T-cells are expected to express a "memory" phenotype (cf 12, 13), and in the present study, they may correspond to some of the UCHL1+ (↔ CD45R0}) memory phenotype) T-cells found in the flare-infiltrates. However, UCHL1-positive T-cells were also found to persist at the previous, 5-week-old patch test site of the placebo group, in which no flare-up was registered, a finding similar to previous observations on nickel (14). Also, the flare-up showed features overlapping at the tissue level with a strong contact allergy reaction to Au (cf 10). This may partly be due to the fact that "the primed tissue condition" was initially induced by the Au patch testing.

In the present study, evidence of a flare-up was noticed within hours of the parenteral injection and this test reaction was biopsied at 48 h. The rapid response suggests that gold itself is involved at a very early stage. Injected gold salt (15) shows a universal distribution and "endogenous" uptake of the injected gold may thus be a significant blood-borne "early inducing factor". Experimentally, Oliveira et al. (16) showed that Au can enhance the release of classical inflammatory mediators from mast cells. This seems to be dependent upon mast cell surface IgE. Askensäge and his group (17) found that the early phase of "elicited skin contact sensitivity" in mice is mediated by serotonin via mast cells sensitized locally by IgE through their FceRI. Notably, the clinical experience is that the present flare-up reactions differ macroscopically from patch test reactions, the former exhibiting more of urticaria-like features. This would be consistent with involvement of "immediate-type" components at the early phases. In the present study, oedema was histologically found at the flare-up site as well as perivascular lymphocytic infiltrates and also a changed distribution of tryptase + mast cells, indirectly suggesting involvement of the mast cells.

Since parenteral gold is expected to be universally distributed, including skin, additional factors must be operative for a localized flare-up to occur at the previous GSTM test site. It is possible that the flare-up phenomenon may consist of two major closely interconnected phases, the initial one being vascular, as discussed above. In the present study, the residual changes or "priming" at the previous patch test site were found to include ELAM-1 endothelial activity as well as persistence of lymphocytic cells.

ELAM-1 is not expressed in normal skin (18, 19), and we therefore conclude that patch testing to gold induces ELAM-1 to become part of the "priming", as indicated in our 6-week placebo group. It is not known if gold, similarly to nickel (20, 21), may induce endothelial gene transcription of adhesion molecules, such as ELAM-1. Alternatively, this may occur via keratinocyte-induced IL-1, known to be involved in contact sensitivity reactions (22). The induced endothelial ELAM-1 was always found to be associated with infiltrates of lymphocytes (cf 23), some of which expressed a memory phenotype (UCHL1). Of special interest is that circulating memory type T-cells have been shown to specifically express surface ligands to ELAM-1 (24). There is also a tendency of prolonged in vivo ELAM-1 expression associated with chronic inflammatory skin lesions (25). Notably, patch-testing to gold in hypersensitive individuals may result in long-lasting tissue reactions, with persistence of lymphocytic infiltrates (cf 10). In other words, ELAM-1 may maintain a certain influx of circulating T cells. Our findings at the gold patch test site indicate that persisting T-lymphocytes and induced endothelial ELAM-1 have a close spatial relationship, suggesting that the induced ELAM-1 may play a role in the persistence of the lymphocytic infiltrate.

Indirectly, we found that the persistent ELAM-1 may be functionally associated with the increase of CD68+ mono-
cytokines and leukocyte proteins during the endogenous flare-up in contact allergy to gold (38). In particular, the rapid increase in blood of IL-1 and TNF-α in allergic patients provoked with GSTM may constitute a functional equivalence to the immunohistochimical changes. Further research should aim at identifying functional connections between possibly gold-activated mast cells (IgE) and locally cell-borne gold (macrophages/APC), as pathogenetically potential factors in the development of flare-up to gold.

ACKNOWLEDGEMENTS

This study was supported by grants from the Swedish Asthma and Allergy Association, from the Swedish Foundation for Health Care Sciences and Allergy Research and from the Swedish Medical Research Council (09024).

REFERENCES

Contact allergy to gold 479


